News & Publications

News

10.08.2014 GlycoVaxyn to Present at 248th ACS National Meeting & Exposition

Michael Wacker, Chief Scientific Officer, will present at the 248th ACS National Meeting & Exposition at 2.25pm, PDT on August 10, 2014 at the InterContinental in San Francisco, USA

01.07.2014 GlycoVaxyn Announces the Initiation of a Phase I Clinical Trial in Collaboration with Janssen

GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced the initiation of a Phase 1 clinical trial of a candidate vaccine to prevent infections caused by Extra-intestinal Pathogenic Escherichia coli (ExPEC), such as urinary tract infections (UTIs).

12.06.2014 GlycoVaxyn to Present at FASEB Microbial Glycobiology Conference

Stefan Kemmler, Group Leader Research, will present at the FASEB Microbial Glycobiology Conference at 9.30am, CDT on June 12, 2014 at the Eagelwood Resort in Itasca, USA

04.06.2014 GlycoVaxyn to Present at IBC Bioconjugates Conference

Michael Wacker, CSO, will present at the IBC Bioconjugates Conference at 4.30pm, PDT on June 04, 2014 at the Grand Hyatt Hotel in San Francisco, USA

29.07.2013 GlycoVaxyn has secured a Strategic Translation Award from the Wellcome Trust

Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that it has secured a Strategic Translation Award from the Wellcome Trust to finance its Shigella program.

26.06.2013 GlycoVaxyn to Present at IBC Bioconjugates Conference

Michael Wacker, CSO will present at the IBC Bioconjugates Conference at 4.45pm PDT on June 26, 2013 at the Hotel Coronado in San Diego, USA

13.06.2013 GlycoVaxyn to Host 3rd Science Day

GlycoVaxyn will host its 3rd Science Day on June 13-14, 2013 in Beaune, France

09.05.2013 GlycoVaxyn to Present at the 9th Annual National Carbohydrate Symposium

Michael Kowarik, Head of Research will present at the 9th Annual National Carbohydrate Symposium at 9.05am MDT on May 09, 2013 at the Banff Park Lodge in Banff, Canada

06.03.2013 GlycoVaxyn Announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors

Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Gréco steps down from the Chairmanship.

04.01.2013 GlycoVaxyn Signs Exclusive License Agreement and Enters Research and Development Collaboration with Janssen Pharmaceuticals, Inc.

GlycoVaxyn AG, a leader in the development of innovative vaccines today announced that Janssen Pharmaceuticals, Inc. has signed an exclusive license agreement and enterd a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology.

19.12.2012 GlycoVaxyn Announces Strategic Collaboration with GlaxoSmithKline

GlycoVaxyn AG, a leader in the development of innovative vaccines today announced a collaboration with GlaxoSmithKline Biologicals (GSK) to develop new bacterial vaccines employing GlycoVaxyn's bio-conjugation technology.

27.08.2012 GlycoVaxyn to Present at the 5th Baltic Meeting on Microbial and Carbohydrates

Michael Kowarik, Head of Research, will present at the 5th Baltic Meeting on Microbial and Carbohydrates at 6.05 p.m. MSK, on September 03 at the Pushkarskaya Sloboda Hotel in Suzdal

09.07.2012 GlycoVaxyn to Present at the 7th Annual Post-Translational Modification Congress

Paula Carranza, MS Expert, will present at the 7th Annual Post-Translational Modification Congress at 5 p.m. CET, on September 27 at the Maritim Hotel in Berlin

01.06.2012 GlycoVaxyn to Present at the 2012 BIO International Convention in Boston

Michael Stucky, Co-founder and CFO, will present at the 2012 BIO International Convention at 10:30 a.m. EDT, on June 20 at the Convention & Exhibition Center in Boston

02.04.2012 GlycoVaxyn to Present at 2nd Annual Vaccine Congress London 2012

Michael Kowarik, Head of Research, will present at the 2nd Annual Vaccine Congress London 2012 at 11:20 a.m. GMT, on April 02 at the Radisson Blu Portman Hotel in London

28.03.2012 GlycoVaxyn to Present at World Congress of Vaccine 2012

Michael Wacker, chief scientific officer, will present at the World Congress of Vaccine 2012 at 8:30 a.m. CST, on March 28 at the Beijing Continental Grand Hotel in Beijing

09.01.2012 GlycoVaxyn to Present at Biotech Showcase 2012

Philippe Dro, chief executive officer, will present at the Biotech Showcase 2012 at 10:30 a.m. PST, on January 9 at the Park 55 Wyndham in San Francisco

03.10.2011 GlycoVaxyn to Present at Sofinnova Japan Biopharma Partnering Conference

Philippe Dro, chief executive officer, will present at the Sofinnova Japan Biopharma Partnering Conference at 12:10 p.m. JST, October 4 at the Conrad Hotel in Tokyo

16.09.2011 GlycoVaxyn to Present at ICAAC Conference

Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

09.09.2011 GlycoVaxyn to Present at Two Investor Conferences

First Annual Biotech in Europe Investor Forum & UBS Global Life Sciences Conference

15.06.2011 GlycoVaxyn to Host Second Annual Science Day

Discuss Challenges and Opportunities in Vaccine Development

08.10.2010 GlycoVaxyn Phase I Clinical Study Shows Positive Data with Shigella dysenteriae Vaccine Candidate

First important step towards the development of a mulitvalent Shigella vaccine against severe diarrheal disease

04.05.2010 GlycoVaxyn and a Harvard University affiliated hospital receive USD 3.4 million NIH grant

Program to leverage GlycoVaxyn Proprietary in vivo conjugation technology

23.02.2010 GlycoVaxyn's First Clinical Study with Bioconjugate Vaccine Initiated

GlycoVaxyn has commenced a Phase I clinical study with its vaccine candidate GVXN SD133 against Shigella dysenteriae.

06.10.2009 GlycoVaxyn Appoints Renowned Vaccinologist Dr. Stanley Plotkin to Supervisory Board

GlycoVaxyn announced today that the world renowned vaccinologist Dr. Stanley A. Plotkin has been elected to its Supervisory Board.

05.03.2009 GlycoVaxyn Announces its Series B Financing Round

GlycoVaxyn AG raises CHF 25 million in Financing led by Edmond de Rothschild Investment Partners.

20.05.2008 GlycoVaxyn Appoints Philippe Dro as CEO

GlycoVaxyn AG announces the appointment of Dr. Philippe Dro as Chief Executive Officer and member of the Supervisory Board. Dr. Dro brings to GlycoVaxyn nearly 20 years entrepreneurial experience in the life science industry.

16.07.2007 Series A Financing and Chairman Appointment

GlycoVaxyn AG completes CHF 11.5 million Series A Financing. Former Aventis Pasteur President Michel Gréco appointed as chairman.

01.06.2007 GlycoVaxyn has Moved to Zurich-Schlieren

We are very pleased to announce that GlycoVaxyn has moved to larger facilities within the biotech cluster in Zurich-Schlieren.

19.10.2006 GlycoVaxyn Wins the Life Sciences Prize 2006

GlycoVaxyn was awarded the Life Sciences Prize 2006, which is under the patronage of the Swiss Biotech Association and the BioValley Basel Association, on October 18th, 2006. The prize recognizes the scientific basis and the significant potential of for economic success of young Swiss startup companies.

06.07.2006 GlycoVaxyn announces its first institutional financing round

GlycoVaxyn announces that it has completed its first institutional financing round in early July 2006, co-led by Index Ventures (www.indexventures.com) and Sofinnova Partners (www.sofinnova.fr). The proceeds from this financing will be used for the validation of GlycoVaxyn’s proprietary bacterial glycosylation technology. The funds are dedicated to advance GlycoVaxyn’ conjugated vaccine development programs against several bacterial pathogens of clinical significance. Furthermore, experimental work will address the widening of the scope of the technology, particularly by including different established carrier proteins as acceptors for bacterial sugar antigens.